GlassScriptPhysician profile
Eve L Patton
NPI 1407865009
$17,840.42
in general payments reported to CMS, 2019-2025
61 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,709 · 2020: $2,314 · 2021: $3,123 · 2022: $3,200 · 2023: $2,558 · 2024: $2,088 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,488 · Education: $7.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,488.19 |
| Education | $7.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,235.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,002.58 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,906.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,460.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,441.69 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $926.12 | 2022-2025 | |
| Lilly USA, LLC | $855.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $642.47 | 2019-2025 | Otezla, Repatha, Repatha |
| Mylan Specialty L.P. | $632.37 | 2020-2024 | Yupelri |
| Astellas Pharma US INC | $546.65 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $368.04 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $337.10 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $317.83 | 2019-2023 | |
| Abbott Laboratories | $271.77 | 2021-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $265.55 | 2024-2025 | Korlym |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eve Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.